Drug or treatment

Sacituzumab clinical trials

• 76Clinical trials
• 52Countries

Newest trials

All recruiting trials (76)

• Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer

  This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07850791

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer

  This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT07811752

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• Sacituzumab tirumotecan with or without pembrolizumab in ovarian clear cell cancer that has come back or spread

  This phase II study tests Sacituzumab tirumotecan alone or with pembrolizumab in adults whose ovarian clear cell cancer has recurred or spread after prior PD-1 therapy.

  Recruiting Phase 2 Tufts Medical Center · Boston, Massachusetts · NCT07718854

• Sac-TMT plus bevacizumab in TNBC with brain metastases

  This phase II, single-arm study tests whether Sac-TMT combined with bevacizumab can help people with triple-negative breast cancer and brain metastases.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07623577

• Patient-reported outcomes of sacituzumab govitecan versus physician‑choice chemotherapy in Chinese metastatic HER2‑negative breast cancer

  This project will test whether sacituzumab govitecan or physician‑choice chemotherapy leads to better patient‑reported quality of life and symptoms for Chinese adults aged 18–75 with metastatic HER2‑negative breast cancer who progressed after first‑line treatment.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07551050

• Sacituzumab tirumotecan plus furmonertinib for advanced EGFR‑mutant non‑squamous lung cancer after EGFR‑TKI and platinum chemotherapy

  This Phase II trial will test whether combining sacituzumab tirumotecan with furmonertinib helps people with advanced EGFR‑mutant non‑squamous NSCLC who progressed after EGFR‑TKI and platinum chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07548060

• Sacituzumab govitecan with bevacizumab vs standard chemotherapy for recurrent platinum-sensitive ovarian cancer after PARP inhibitor maintenance

  This phase II study tests whether sacituzumab govitecan plus bevacizumab can help people with recurrent platinum-sensitive ovarian cancer, after PARP inhibitor maintenance, more than the usual carboplatin, PLD, and bevacizumab treatment.

  Recruiting at 23 sites Phase 2 National Cancer Institute (NCI) · Fayetteville, Arkansas and 22 other locations · NCT07504588

• Pre-surgery sacituzumab govitecan plus tagitanlimab for operable head and neck squamous cell carcinoma

  This trial tests whether giving sacituzumab govitecan together with tagitanlimab before surgery helps people with resectable head and neck squamous cell carcinoma have better tumor responses and outcomes.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07492914

• Sacituzumab Tirumotecan in SMARCB1-Deficient Renal Medullary Carcinoma

  Aims to see if sacituzumab tirumotecan can help control advanced SMARCB1-deficient renal medullary carcinoma in patients whose disease has progressed after prior therapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07438626

• Sacituzumab tirumotecan versus non‑platinum chemotherapy for advanced bladder cancer

  This trial will test whether sacituzumab tirumotecan can help people with advanced urothelial (bladder) cancer live longer than certain non‑platinum chemotherapies after their disease worsens following prior treatments.

  Recruiting at 113 sites Phase 3 Merck Sharp & Dohme LLC · Newport Beach, California and 112 other locations · NCT07419295

• Advanced NSCLC with actionable mutations after targeted therapy and chemo: expanded Lung-MAP treatment

  This phase II trial tests whether sacituzumab govitecan alone, ivonescimab alone, or the combination of both can help people with advanced or recurrent NSCLC that has a targetable genetic change.

  Recruiting at 41 sites Phase 2 SWOG Cancer Research Network · Berkeley, California and 40 other locations · NCT07393555

• Osimertinib plus sacituzumab tirumotecan for EGFR-mutant advanced non-small cell lung cancer with persistent ctDNA after initial osimertinib

  This trial will test whether adding sacituzumab tirumotecan to osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer whose blood ctDNA remains positive after one cycle of osimertinib.

  Recruiting at 4 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 3 other locations · NCT07375316

• Sacituzumab govitecan with atezolizumab or durvalumab as maintenance for extensive-stage small cell lung cancer

  This study tests whether adding sacituzumab govitecan to ongoing atezolizumab or durvalumab can better control tumors in adults with extensive-stage small cell lung cancer after initial platinum-based chemotherapy.

  Recruiting Phase 2 Henry Ford Health System · Detroit, Michigan · NCT07339059

• Neoadjuvant sacituzumab tirumotecan with or without osimertinib for resectable EGFR‑mutated non‑small cell lung cancer

  This trial will test whether giving sacituzumab tirumotecan alone or together with osimertinib before surgery helps people with resectable EGFR‑mutated non‑small cell lung cancer.

  Recruiting Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Beijing · NCT07329322

• Neoadjuvant sacituzumab tirumotecan plus limertinib for potentially resectable stage III EGFR‑mutant non‑small cell lung cancer

  This trial will test whether giving sacituzumab tirumotecan with limertinib before surgery can shrink stage III EGFR‑mutant non‑small cell lung cancers enough to allow safe resection.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT07323056

• Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

  This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

  Recruiting at 177 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 176 other locations · NCT07318558

• First-line Sacituzumab Govitecan for Advanced Untreated Triple-Negative Breast Cancer

  This study tests whether Sacituzumab Govitecan can slow disease progression when given as a first treatment to adults with advanced triple-negative breast cancer who have not yet received treatment in the advanced setting.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia · NCT07299409

• Sacituzumab tirumotecan plus QL1706 for recurrent or metastatic cervical cancer

  This study will test whether combining sacituzumab tirumotecan (a TROP2-targeted antibody‑drug conjugate) with QL1706 (a dual PD‑1/CTLA‑4 antibody) helps people with recurrent or metastatic cervical cancer who have already received platinum therapy.

  Recruiting at 2 sites Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian and 13 other locations · NCT07256236

• Sacituzumab tirumotecan plus pembrolizumab as first-line maintenance for metastatic cervical cancer

  This trial tests whether adding the antibody-drug conjugate sacituzumab tirumotecan to pembrolizumab (with or without bevacizumab) as maintenance treatment can help people with metastatic cervical cancer live longer or keep the cancer from growing.

  Recruiting at 191 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 190 other locations · NCT07216703

• Sacituzumab tirumotecan plus tagitanlimab for aggressive and neuroendocrine prostate cancer

  This trial tests whether combining sacituzumab tirumotecan with the immunotherapy tagitanlimab helps people with aggressive variant or neuroendocrine prostate cancer that has progressed after newer hormonal treatments.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07179783

• Sacituzumab tirumotecan plus pucotenlimab for advanced cholangiocarcinoma

  This trial will test whether combining sacituzumab tirumotecan with pucotenlimab can help people with unresectable or metastatic cholangiocarcinoma.

  Recruiting Phase 2 Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07105852

• Sacituzumab Tirumotecan plus Toripalimab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma

  This trial will test whether the antibody-drug conjugate sacituzumab tirumotecan combined with the PD-1 inhibitor toripalimab helps people with recurrent or metastatic head and neck squamous cell carcinoma whose tumors are Trop-2 positive and have PD-L1 CPS ≥1.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07088211

• Sacituzumab tirumotecan with or without tislelizumab for advanced thyroid cancer

  This trial tests sacituzumab tirumotecan, given alone or together with the immunotherapy tislelizumab, in adults with unresectable or metastatic anaplastic, poorly differentiated, or radioactive iodine‑refractory differentiated thyroid cancer to see if it slows disease or improves survival.

  Recruiting Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT07068542

• Sacituzumab govitecan plus cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial will test whether combining sacituzumab govitecan with cetuximab works and is safe for people whose head and neck squamous cell cancer has returned or spread after prior immunotherapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07063212

• Naxitamab plus sacituzumab govitecan for metastatic triple-negative breast cancer

  This trial will test whether combining naxitamab with sacituzumab govitecan helps adults with metastatic triple-negative breast cancer.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07011654

• Real-world look at SKB264 in HER2-negative breast cancer that has come back or spread

  This real-world study tests sacituzumab tirumotecan (SKB264) alone or with others in adults with recurrent or metastatic HER2-negative breast cancer.

  Recruiting at 12 sites Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Hefei, Anhui and 18 other locations · NCT06993506

• Trilaciclib given before sacituzumab tirumotecan to protect bone marrow in EGFR-mutated advanced NSCLC

  This trial will test whether giving trilaciclib before sacituzumab tirumotecan helps protect the blood and reduce blood-related side effects in people with advanced EGFR‑mutated non-small cell lung cancer who have stopped responding to EGFR-TKI therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06992739

• Combination therapy for advanced triple-negative breast cancer

  This study is testing a new combination of two drugs to see if it can help people with advanced triple-negative breast cancer live longer and feel better.

  Recruiting Peking University Cancer Hospital & Institute · Beijing · NCT06991790

• Sacituzumab tirumotecan plus pembrolizumab and chemotherapy for high-risk early triple-negative and HR-low/HER2-negative breast cancer

  This trial will test whether adding sacituzumab tirumotecan and pembrolizumab to chemotherapy helps people with high‑risk early-stage triple‑negative or HR‑low/HER2‑negative breast cancer have fewer cancer cells in their tumors and lymph nodes before surgery.

  Recruiting at 331 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 334 other locations · NCT06966700

• Observing the effects of Sacituzumab Govitecan in metastatic breast cancer

  This study is testing how well Sacituzumab Govitecan works and how safe it is for people with metastatic HER-2 negative breast cancer who have already tried at least two other treatments.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06966141

• Sacituzumab govitecan with nivolumab, with or without relatlimab, for metastatic triple-negative breast cancer

  This trial tests whether adding nivolumab alone or nivolumab plus relatlimab to sacituzumab govitecan helps people with metastatic triple-negative breast cancer who have had one prior line of chemotherapy.

  Recruiting Phase 1/2 Yale University · New Haven, Connecticut · NCT06963905

• Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab alone for pMMR endometrial cancer

  This trial tests whether adding sacituzumab tirumotecan to pembrolizumab helps people with advanced or recurrent mismatch repair–proficient endometrial cancer live longer without their cancer getting worse compared to pembrolizumab alone.

  Recruiting at 266 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 270 other locations · NCT06952504

• Testing a new dosing schedule of sacituzumab govitecan for advanced triple-negative breast cancer

  This study is testing a new way to give a cancer drug called sacituzumab govitecan to see if it is safe and effective for people with advanced triple-negative breast cancer.

  Recruiting at 15 sites Phase 1/2 Gilead Sciences · Los Angeles, California and 15 other locations · NCT06926920

• Sacituzumab govitecan for advanced salivary gland and differentiated thyroid cancers

  This study will try sacituzumab govitecan in adults whose salivary gland cancer or radioactive-iodine–refractory differentiated thyroid cancer has spread or come back and cannot be removed by surgery.

  Recruiting Phase 2 National University Hospital, Singapore · Singapore · NCT06923826

• Treatment for triple-negative breast cancer using sacituzumab tirumotecan and pembrolizumab

  This study is testing if a new treatment combining sacituzumab tirumotecan and pembrolizumab can help people with triple-negative breast cancer live longer and keep their cancer from getting worse compared to regular chemotherapy.

  Recruiting at 274 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 284 other locations · NCT06841354

• Combination treatment for advanced solid tumors using Invikafusp Alfa and Sacituzumab Govitecan

  This study is testing a new combination treatment of Invikafusp Alfa and Sacituzumab Govitecan to see if it helps people with advanced solid tumors, like certain types of breast cancer, feel better.

  Recruiting at 8 sites Phase 1/2 Marengo Therapeutics, Inc. · Los Angeles, California and 7 other locations · NCT06827613

• Evaluating a new treatment for recurrent ovarian cancer

  This study is testing a new treatment for women with recurrent ovarian cancer to see if it helps them live longer and feel better compared to standard care.

  Recruiting at 201 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 201 other locations · NCT06824467

• Comparing sacituzumab govitecan to standard care for advanced small cell lung cancer

  This study is testing whether a new treatment called sacituzumab govitecan can help people with advanced small cell lung cancer live longer and feel better compared to standard care.

  Recruiting at 206 sites Phase 3 Gilead Sciences · Anchorage, Alaska and 218 other locations · NCT06801834

• Sacituzumab govitecan for HER2‑negative metastatic breast cancer in China

  This will test how well sacituzumab govitecan works and how safe it is for adults in China with HER2‑negative metastatic breast cancer.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06784921

• Combination therapy for high-risk muscle-invasive bladder cancer

  This study is testing if a combination of two cancer drugs can help people with high-risk bladder cancer stay cancer-free after surgery.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06682728

• Treatment for extensive small cell lung cancer using chemotherapy and immunotherapy

  This study is testing a new combination of chemotherapy and immunotherapy to see if it helps people with extensive small cell lung cancer who haven't had treatment before.

  Recruiting Phase 2 Shaare Zedek Medical Center · Jerusalem, Israel · NCT06667167

• Genomic and transcriptomic markers predicting response to sacituzumab govitecan after trastuzumab deruxtecan in ER+/HER2-low metastatic breast cancer

  This trial will test whether DNA and RNA features from a fresh tumor biopsy can predict who responds to sacituzumab govitecan in people with ER-positive, HER2-low metastatic breast cancer who progressed after trastuzumab deruxtecan.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia · NCT06665178

• Preventing neutropenia from sacituzumab govitecan in metastatic triple-negative breast cancer

  This trial tests sacituzumab govitecan given with pegfilgrastim to see if it prevents low white blood cell counts in people with metastatic triple-negative breast cancer who have had one or two prior chemotherapy regimens.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT06616987

• Pembrolizumab plus sacituzumab govitecan versus standard treatments for advanced urothelial cancer

  This trial will test whether adding sacituzumab govitecan to pembrolizumab works better than standard chemotherapy options for adults with locally advanced or metastatic urothelial cancer who have progressed after prior therapy.

  Recruiting at 161 sites Phase 3 National Cancer Institute (NCI) · Phoenix, Arizona and 162 other locations · NCT06524544

• Treatment with Sacituzumab Govitecan for Mesothelioma

  This study tests if a new treatment called sacituzumab govitecan can help people with mesothelioma who have already tried other therapies feel better and manage their disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06477419

• Sacituzumab govitecan plus intrathecal pemetrexed for leptomeningeal metastases from HER2-negative breast cancer

  This tests whether sacituzumab govitecan combined with intrathecal pemetrexed can help people with leptomeningeal metastases from HER2-negative breast cancer.

  Recruiting Phase 1/2 Guangzhou Medical University · Huizhou, Guangdong · NCT06462092

• Treatment for lung cancer patients who had surgery but are not disease-free

  This study is testing two new immunotherapy treatments for lung cancer patients who have had surgery but still have some disease to see if they can help them stay cancer-free longer.

  Recruiting at 31 sites Phase 3 Fundación GECP · Alicante, Alicante and 31 other locations · NCT06431633

• Combining pembrolizumab with or without sacituzumab tirumotecan for advanced lung cancer treatment

  This study is testing if adding a new drug called sacituzumab tirumotecan to the standard treatment with pembrolizumab can help people with advanced lung cancer live longer.

  Recruiting at 172 sites Phase 3 Merck Sharp & Dohme LLC · Little Rock, Arkansas and 216 other locations · NCT06422143

• Combining sacituzumab govitecan and bevacizumab for treating brain metastases in lung cancer

  This study is testing if a combination of two drugs, sacituzumab govitecan and bevacizumab, can help shrink brain tumors in patients with lung cancer who haven't responded to other treatments.

  Recruiting at 3 sites Phase 2 Maastricht University Medical Center · Amsterdam and 2 other locations · NCT06401824

• Combination treatment for triple-negative breast cancer after surgery

  This study is testing a new combination treatment for people with triple-negative breast cancer who didn't fully respond to earlier therapy after surgery to see if it helps them stay cancer-free longer.

  Recruiting at 299 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 313 other locations · NCT06393374

• Using sacituzumab govitecan for advanced esophageal squamous cell carcinoma

  This study is testing a new treatment called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma whose previous treatments didn’t work, to see if it can help them.

  Recruiting Phase 2 National Taiwan University Hospital · Taipei · NCT06329869

• Comparing sacituzumab tirumotecan and pembrolizumab to standard treatment for advanced breast cancer

  This study is testing if a new treatment combining sacituzumab tirumotecan and pembrolizumab can help people with advanced breast cancer live longer without their disease getting worse compared to standard treatments.

  Recruiting at 181 sites Phase 3 Merck Sharp & Dohme LLC · Chandler, Arizona and 258 other locations · NCT06312176

• Assessing the effectiveness of pembrolizumab with or without sacituzumab tirumotecan in lung cancer patients after surgery

  This study is testing if adding a new drug called sacituzumab tirumotecan to pembrolizumab can help lung cancer patients who had surgery live longer without their cancer coming back.

  Recruiting at 259 sites Phase 3 Merck Sharp & Dohme LLC · Little Rock, Arkansas and 270 other locations · NCT06312137

• Evaluating the effectiveness of sacituzumab govitecan in specific breast cancer patients

  This study is testing if a drug called sacituzumab govitecan can help people with advanced hormone receptor-positive breast cancer who have already been treated with another medication.

  Recruiting at 3 sites Phase 2 Baptist Health South Florida · Miami, Florida and 2 other locations · NCT06263543

• Testing a new treatment for advanced thymic tumors

  This study is testing a new drug to see if it can help adults with advanced thymic tumors who haven't had success with other treatments.

  Recruiting at 4 sites Phase 2 Georgetown University · Palo Alto, California and 3 other locations · NCT06248515

• Using Sacituzumab Govitecan for advanced colorectal cancer

  This study is testing a new drug called Sacituzumab Govitecan to see if it can help people with advanced colorectal cancer who haven't had success with other treatments.

  Recruiting Phase 2/3 University Hospital Heidelberg · Heidelberg, Baden-Wurttemberg · NCT06243393

• Evaluating the effectiveness of sacituzumab govitecan for metastatic triple-negative breast cancer

  This study is testing how well a new treatment called sacituzumab govitecan works for people with metastatic triple-negative breast cancer and whether it is safe to use.

  Recruiting Regina Elena Cancer Institute · Rome, Rome · NCT06240195

• Combining Sacituzumab Govitecan and Zimberelimab with Stereotactic Radiation for Metastatic Triple Negative Breast Cancer with Brain Metastases

  This study is testing if combining two treatments, Sacituzumab Govitecan and Zimberelimab, with targeted radiation can help adults with metastatic triple negative breast cancer that has spread to the brain feel better compared to just using Sacituzumab Govitecan alone.

  Recruiting Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06238921

• Treatment for advanced or metastatic breast cancer using sacituzumab govitecan

  This study is testing if a new drug called sacituzumab govitecan can help people with advanced breast cancer who haven't had success with other treatments.

  Recruiting at 2 sites Phase 2 SOLTI Breast Cancer Research Group · Badalona, Barcelona and 9 other locations · NCT06236269

• Treatment for advanced thyroid cancers using sacituzumab govitEcan

  This study is testing a new drug called sacituzumab govitEcan to see if it can help people with advanced thyroid cancers that don't respond to traditional treatments.

  Recruiting at 9 sites Phase 2 Grupo Espanol de Tumores Neuroendocrinos · Barcelona and 10 other locations · NCT06235216

• Combining sacituzumab tirumotecan with pembrolizumab for advanced lung cancer

  This study is testing if combining two cancer treatments, sacituzumab tirumotecan and pembrolizumab, can help people with advanced lung cancer live longer compared to just using pembrolizumab alone.

  Recruiting at 154 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 219 other locations · NCT06170788

• Combining two drugs to treat rare genitourinary tumors

  This study is testing whether a combination of two drugs can help adults with rare and aggressive genitourinary tumors feel better and improve their treatment options.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06161532

• Comparing two treatments for low-risk triple-negative breast cancer

  This study is testing whether adding pembrolizumab to sacituzumab govitecan can help people with low-risk triple-negative breast cancer do better after their initial treatment.

  Recruiting at 38 sites Phase 3 Women's Cancer Study Group GmbH · Baden-Baden, Baden-Wurttemberg and 42 other locations · NCT06081244

• Combining sacituzumab govitecan with capecitabine for advanced gastrointestinal cancers

  This study is testing if combining two cancer treatments, sacituzumab govitecan and capecitabine, can help people with advanced gastrointestinal cancers that haven't improved with standard treatments.

  Recruiting Phase 1 Henry Ford Health System · Detroit, Michigan · NCT06065371

• Combining Sacituzumab Govitecan with Cisplatin for Ovarian and Endometrial Cancer

  This study is testing a new combination of two drugs, sacituzumab govitecan and cisplatin, to see if it can effectively treat people with recurrent ovarian and endometrial cancers that respond to platinum-based treatments.

  Recruiting Phase 1/2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT06040970

• Treatment for recurrent or persistent cervical cancer using sacituzumab govitecan

  This study is testing a new treatment called sacituzumab govitecan to see if it can help people with recurrent or persistent cervical cancer who have already tried chemotherapy.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT05838521

• Combining targeted therapy with radiation for bladder cancer treatment

  This study is testing if a new targeted treatment combined with radiation can safely help people with muscle-invasive bladder cancer keep their bladders instead of needing surgery.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT05833867

• Combination treatment for triple negative breast cancer after surgery

  This study is testing if a new combination of two cancer drugs can help adults with triple negative breast cancer who still have cancer after surgery feel better and live longer.

  Recruiting at 290 sites Phase 3 Gilead Sciences · Birmingham, Alabama and 377 other locations · NCT05633654

• Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial cancer

  This trial tests whether combining sacituzumab govitecan and enfortumab vedotin, with pembrolizumab in some patients, helps people with metastatic urothelial carcinoma who have progressed after platinum chemotherapy and PD‑1/PD‑L1 inhibitors.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04724018

• Evaluating sacituzumab govitecan for advanced solid tumors in patients with liver impairment

  This study is testing a new cancer treatment called sacituzumab govitecan to see if it's safe and effective for people with advanced tumors who also have liver problems.

  Recruiting at 13 sites Phase 1 Gilead Sciences · Long Beach, California and 14 other locations · NCT04617522

• Treatment for recurrent glioblastoma using Sacituzumab Govitecan

  This study is testing a new treatment called Sacituzumab Govitecan to see if it can help people with recurrent glioblastoma who haven't responded to standard therapies.

  Recruiting at 3 sites Phase 2 The University of Texas Health Science Center at San Antonio · Cleveland, Ohio and 2 other locations · NCT04559230

• Testing Sacituzumab Govitecan with or without Pembrolizumab for metastatic triple-negative breast cancer

  This study is testing whether a new cancer drug called Sacituzumab Govitecan, alone or with another drug called Pembrolizumab, can help people with metastatic triple-negative breast cancer that hasn't been treated before.

  Recruiting at 15 sites Phase 2 Dana-Farber Cancer Institute · Stamford, Connecticut and 14 other locations · NCT04468061

• Atezolizumab and sacituzumab govitecan to prevent recurrence in triple-negative breast cancer

  This trial tests whether combining sacituzumab govitecan with atezolizumab can prevent cancer from coming back in people with triple-negative breast cancer who have residual disease after pre-surgery chemotherapy and detectable circulating tumor DNA.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · San Francisco, California and 6 other locations · NCT04434040

• Evaluating sacituzumab govitecan for localized triple negative breast cancer

  This study is testing a new drug called sacituzumab govitecan for people with localized triple negative breast cancer to see if it can help them.

  Recruiting at 4 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 4 other locations · NCT04230109

Quick answers

How many clinical trials of Sacituzumab are recruiting right now?

76, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 52 countries. The most sites are in United States (39 trials), China (28 trials), Spain (18 trials), Canada (16 trials), Italy (16 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 39, Phase 3: 18, Phase 1/2: 8, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →